Acute phase after haematopoietic stem cell transplantation

L. Graf; M. Stern

doi:10.5482/ha-1176

Hämostaseologie, Table of Contents

Hamostaseologie 2012; 32(01): 56-62
DOI: 10.5482/ha-1176

Review

Schattauer GmbH

Acute phase after haematopoietic stem cell transplantation

Bleeding and thrombotic complicationsDie akute Phase nach StammzelltransplantationBlutungen und thrombotische Komplikationen

L. Graf

¹Stem Cell Transplant Team and Division of Haematology, University Hospital Basel, Switzerland

,

M. Stern

¹Stem Cell Transplant Team and Division of Haematology, University Hospital Basel, Switzerland

› Author Affiliations

Abstract

Summary

The transplantation of allogeneic or autologous haematopoietic stem cells is an established treatment for many malignant and non-malignant diseases of the bone marrow. Intensive cytoreductive regimens administered before transplantation induce prolonged and severe cytopenia of all haematopoietic lineages. Thrombocytopenia leads to an increased risk of bleeding, which may be further aggravated by consumption of plasmatic factors as a result of tumour lysis or after antibody administration. At the same time, patients after transplantation are also at increased risk of thrombotic complications. Endothelial damage induced by radio-and chemotherapy, indwelling catheters, prolonged immobilization and a high incidence of systemic infection all contribute to the frequent occurrence of thromboembolic events in this population.

This review discusses the incidence and risk factors for haemorrhagic and thrombotic complications after stem cell transplantation. Special emphasis is given to complications occurring specifically in the context of transplantation such as diffuse alveolar haemorrhage, haemorrhagic cystitis, veno-occlusive disease, and transplant associated microangiopathy.

Zusammenfassung

Die Transplantation autologer oder allogener hämatopoietischer Stammzellen ist Routine in der Therapie maligner und nicht maligner Knochenmarkserkrankungen. Die zytoreduktive Therapie vor Transplantation induziert in aller Regel eine schwere und prolongierte Zyto penie aller drei Blutzellreihen. Die Thrombozytopenie führt dabei zu einem erhöhten Risiko von Blutungskomplikationen. Dieses Risiko kann zusätzlich verstärkt werden durch Veränderungen der plasmatischen Gerinnung als Folge einer Tumorlyse oder nach einer Antikörpertherapie. Patienten nach Transplantation erleiden auch häufig thrombotische Komplikationen. Chemo-und Radiotherapie-induzierte Endothelschäden, Venenkatheter, Immobilisation und häufige Infektionen tragen alle zu einem erhöhten Risiko von Thrombosen bei.

Diese Übersichtsarbeit diskutiert die Inzidenz und Risikofaktoren für Blutungs und thrombotische Komplikationen nach Stammzelltransplantation. Dabei wird insbesondere auch auf Komplikationen eingegangen, welche spezifisch nach Transplantation auftreten, wie die diffuse alveoläre Hämorrhagie, die hämorrhagische Zystitis, die Venenverschluss-Krankheit, sowie die Transplantations-assoziierte Mikroangiopathie.

Keywords

Haematopoietic stem cell transplantation - diffuse alveolar haemorrhage - haemorrhagic cystitis - veno-occlusive disease - transplantassociated microangiopathy

Schlüsselwörter

Stammzelltransplantation - diffuse alveoläre Hämorrhagie - hämorrhagische Zystitis - Venenverschlusskrankheit - transplantationsassoziierte Mikroangiopathie

Full Text

References

References
1 Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354: 1813-1826.
2 Korbling M, Freireich EJ. Twenty-five years of peripheral blood stem cell transplantation. Blood 2011; 117: 6411-6416.
3 Nadir Y, Brenner B. Hemorrhagic and thrombotic complications in bone marrow transplant recipients. Thromb Res 2007; 120 (Suppl. 02) S92-S98.
4 Carreras E, Diaz-Ricart M. The role of the endothelium in the short-term complications of hematopoietic SCT. Bone Marrow Transplant. 2011 doi:10.1038/bmt.2011.65
5 Palomo M, Diaz-Ricart M, Carbo C. et al. Endothelial dysfunction after hematopoietic stem cell transplantation: role of the conditioning regimen and the type of transplantation. Biol Blood Marrow Transplant 2010; 16: 985-993.
6 Tichelli A, Gratwohl A. Vascular endothelium as ‘novel’ target of graft-versus-host disease. Best Pract Res Clin Haematol 2008; 21: 139-148.
7 Nadir Y, Hoffman R, Brenner B. Drug-related thrombosis in hematologic malignancies. Rev Clin Exp Hematol 2004; 08: E4.
8 Gordon B, Haire W, Kessinger A. et al. High frequency of antithrombin 3 and protein C deficiency following autologous bone marrow transplantation for lymphoma. Bone Marrow Transplant 1991; 08: 497-502.
9 Collins P, Roderick A, O’Brien D. et al. Factor VIIa and other haemostatic variables following bone marrow transplantation. Thromb Haemost 1994; 72: 28-32.
10 Collins PW, Gutteridge CN, O’Driscoll A. et al. Von Willebrand factor as a marker of endothelial cell activation following BMT. Bone Marrow Transplant 1992; 10: 499-506.
11 Salat C, Holler E, Reinhardt B. et al. Parameters of the fibrinolytic system in patients undergoing BMT: elevation of PAI-1 in veno-occlusive disease. Bone Marrow Transplant 1994; 14: 747-750.
12 Klerk CP, Smorenburg SM, Otten HM. et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23: 2130-2135.
13 Kakkar AK, Levine MN, Kadziola Z. et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22: 1944-1948.
14 Gerber DE, Segal JB, Levy MY. et al. The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention. Blood 2008; 112: 504-510.
15 Pihusch R, Salat C, Schmidt E. et al. Hemostatic complications in bone marrow transplantation: a retrospective analysis of 447 patients. Transplantation 2002; 74: 1303-1309.
16 Holler E, Kolb HJ, Greinix H. et al. Bleeding events and mortality in SCT patients: a retrospective study of hematopoietic SCT patients with organ dysfunctions due to severe sepsis or GVHD. Bone Marrow Transplant 2009; 43: 491-497.
17 Pihusch M. Bleeding complications after hematopoietic stem cell transplantation. Semin Hematol 2004; 41 (1 Suppl 1): 93-100.
18 Nevo S, Vogelsang GB. Acute bleeding complications in patients after bone marrow transplantation. Curr Opin Hematol 2001; 08: 319-325.
19 Rysler C, Stoffel N, Buser A. et al. Effect of betablockers, Ca²⁺ antagonists, and benzodiazepines on bleeding incidence in patients with chemotherapy induced thrombocytopenia. Platelets 2010; 21: 77-83.
20 Dominietto A, Raiola AM, van Lint MT. et al. Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graftversus-host disease, donor type, cytomegalovirus infections and cell dose. Br J Haematol 2001; 112: 219-227.
21 Najima Y, Ohashi K, Miyazawa M. et al. Intracranial hemorrhage following allogeneic hematopoietic stem cell transplantation. Am J Hematol 2009; 84: 298-301.
22 Socie G, Schmoor C, Bethge WA. et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATGFresenius. Blood 2011; 117: 6375-6382.
23 Pihusch R, Holler E, Muhlbayer D. et al. The impact of antithymocyte globulin on short-term toxicity after allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 30: 347-354.
24 Majhail NS, Parks K, Defor TE, Weisdorf DJ. Diffuse alveolar hemorrhage and infection-associated alveolar hemorrhage following hematopoietic stem cell transplantation: related and high-risk clinical syndromes. Biol Blood Marrow Transplant 2006; 12: 1038-1046.
25 Lewis ID, DeFor T, Weisdorf DJ. Increasing incidence of diffuse alveolar hemorrhage following allogeneic bone marrow transplantation: cryptic etiology and uncertain therapy. Bone Marrow Transplant 2000; 26: 539-543.
26 Afessa B, Tefferi A, Litzow MR, Peters SG. Outcome of diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients. Am J Respir Crit Care Med 2002; 166: 1364-1368.
27 Afessa B, Abdulai RM, Kremers WK. et al. Risk factors and outcome of pulmonary complications after autologous hematopoietic stem cell transplant (HSCT). Chest. 2011 doi: 10.1378/chest.10-2889.
28 Raptis A, Mavroudis D, Suffredini A. et al. High-dose corticosteroid therapy for diffuse alveolar hemorrhage in allogeneic bone marrow stem cell transplant recipients. Bone Marrow Transplant 1999; 24: 879-883.
29 Wanko SO, Broadwater G, Folz RJ, Chao NJ. Diffuse alveolar hemorrhage: retrospective review of clinical outcome in allogeneic transplant recipients treated with aminocaproic acid. Biol Blood Marrow Transplant 2006; 12: 949-953.
30 Pastores SM, Papadopoulos E, Voigt L, Halpern NA. Diffuse alveolar hemorrhage after allogeneic hematopoietic stem-cell transplantation: treatment with recombinant factor VIIa. Chest 2003; 124: 2400-2403.
31 Hicks K, Peng D, Gajewski JL. Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa. Bone Marrow Transplant 2002; 30: 975-978.
32 Estella A, Jareno A, Perez-Bello LFontaina. Intrapulmonary administration of recombinant activated factor VII in diffuse alveolar haemorrhage: a report of two case stories. Cases J 2008; 01: 150.
33 Heslet L, Nielsen JD, Levi M. et al. Successful pulmonary administration of activated recombinant factor VII in diffuse alveolar hemorrhage. Crit Care 2006; 10: R177.
34 Silva PLde, Patah PA, Saliba RM. et al. Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type. Haematologica 2010; 95: 1183-1190.
35 Gorczynska E, Turkiewicz D, Rybka K. et al. Incidence, clinical outcome, and management of virusinduced hemorrhagic cystitis in children and adolescents after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2005; 11: 797-804.
36 Bogdanovic G, Priftakis P, Giraud G. et al. Association between a high BK virus load in urine samples of patients with graft-versus-host disease and development of hemorrhagic cystitis after hematopoietic stem cell transplantation. J Clin Microbiol 2004; 42: 5394-5396.
37 Giraud G, Priftakis P, Bogdanovic G. et al. BK-viruria and haemorrhagic cystitis are more frequent in allogeneic haematopoietic stem cell transplant patients receiving full conditioning and unrelated-HLA-mismatched grafts. Bone Marrow Transplant 2008; 41: 737-742.
38 Leung AY, Yuen KY, Kwong YL. Polyoma BK virus and haemorrhagic cystitis in haematopoietic stem cell transplantation: a changing paradigm. Bone Marrow Transplant 2005; 36: 929-937.
39 Dalianis T, Ljungman P. Full myeloablative conditioning and an unrelated HLA mismatched donor increase the risk for BK virus-positive hemorrhagic cystitis in allogeneic hematopoetic stem cell transplanted patients. Anticancer Res 2011; 31: 939-944.
40 Cesaro S, Hirsch HH, Faraci M. et al. Cidofovir for BK virus-associated hemorrhagic cystitis: a retrospective study. Clin Infect Dis 2009; 49: 233-240.
41 Pihusch M, Bacigalupo A, Szer J. et al. Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. J Thromb Haemost 2005; 03: 1935-1944.
42 Tsakiris DA, Tichelli A. Thrombotic complications after haematopoietic stem cell transplantation: early and late effects. Best Pract Res Clin Haematol 2009; 22: 137-145.
43 Gonsalves A, Carrier M, Wells PS. et al. Incidence of symptomatic venous thromboembolism following hematopoietic stem cell transplantation. J Thromb Haemost 2008; 06: 1468-1473.
44 Stoffel N, Rysler C, Buser A. et al. Leukocyte count and risk of thrombosis in patients undergoing haematopoietic stem cell transplantation or intensive chemotherapy. Thromb Haemost 2010; 103: 1228-1232.
45 Pinomaki A, Volin L, Joutsi-Korhonen L. et al. Early thrombin generation and impaired fibrinolysis after SCT associate with acute GVHD. Bone Marrow Transplant 2010; 45: 730-737.
46 Pihusch M, Lohse P, Reitberger J. et al. Impact of thrombophilic gene mutations and graft-versushost disease on thromboembolic complications after allogeneic hematopoietic stem-cell transplantation. Transplantation 2004; 78: 911-918.
47 Abdelkefi A, Ben Romdhane N, Kriaa A. et al. Prevalence of inherited prothrombotic abnormalities and central venous catheter-related thrombosis in haematopoietic stem cell transplants recipients. Bone Marrow Transplant 2005; 36: 885-889.
48 Lagro SW, Verdonck LF, Borel IHRinkes, Dekker AW. No effect of nadroparin prophylaxis in the prevention of central venous catheter (CVC)-associated thrombosis in bone marrow transplant recipients. Bone Marrow Transplant 2000; 26: 1103-1106.
49 Magagnoli M, Masci G, Castagna L. et al. Prophylaxis of central venous catheter-related thrombosis with minidose warfarin in patients treated with high-dose chemotherapy and peripheral-blood stem-cell transplantation: retrospective analysis of 228 cancer patients. Am J Hematol 2006; 81: 1-4.
50 Ho VT, Revta C, Richardson PG. Hepatic venoocclusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 41: 229-237.
51 Salat C, Holler E, Kolb HJ. et al. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. Blood 1997; 89: 2184-2188.
52 Richardson PG, Elias AD, Krishnan A. et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood 1998; 92: 737-744.
53 Richardson PG, Murakami C, Jin Z. et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002; 100: 4337-4343.
54 Chalandon Y, Roosnek E, Mermillod B. et al. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2004; 10: 347-354.
55 Dignan F, Gujral D, Ethell M. et al. Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from venoocclusive disease. Bone Marrow Transplant 2007; 40: 79-82.
56 Laskin BL, Goebel J, Davies SM, Jodele S. Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Blood 2011; 118: 1452-1462.
57 Ho VT, Cutler C, Carter S. et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 571-5715.
58 Au WY, Ma ES, Lee TL. et al. Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab. Br J Haematol 2007; 137: 475-478.
59 Nurnberger J, Philipp T, Witzke O. et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009; 360: 542-544.
60 McDonald GB, Sharma P, Matthews DE. et al. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 04: 116-122.
61 Jones RJ, Lee KS, Beschorner WE. et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778-783.
62 Ruutu T, Barosi G, Benjamin RJ. et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica 2007; 92: 95-100.